The approval was based on a biomarker subgroup analysis of 387 patients with HRD-positive tumours from the Phase 3 PAOLA-1 trial, which showed that olaparib with bevacizumab reduced the risk of disease progression or death vs bevacizumab alone (HR 0.33 95%CI, 0.25-0.45).